Dr Mingyi Chen

Dr. Mingyi Chen

Dr Chen is a board certified in pathology (anatomic and clinical pathology) with a subspecialty in hematology. His clinical interests include hematopathology, immunology, and molecular pathology for the diagnosis of lymphoma, leukemia, flow cytometry, bone marrow transplant pathology, diagnostic molecular pathology by next-generation sequencing (NGS) mutational analysis, and cancer immunotherapy. He has served as medical director of the CLIA labs at Shriner hospital of northern California and Moncrief cancer institute of UTSW and Richardson clinics. He is actively involved in the institutional performance improvement committee meetings. He has extensive experience in supervising the clinical diagnostic laboratory and overviewing quality assurance, quality control, proficiency surveys, and patient data. He provides educational direction for medical students, residents, fellows, and medical laboratory staff.His research interests include atherosclerosis, thrombosis, vascular biology, lipid metabolism, graft-vs-host disease (GVHD), molecular pathogenesis of lymphoma and leukemia, NK cells in tumor immunology, viral infections, and cancer stem cells. His current research focuses on the genetic and epigenetic alterations of hematopoietic cells. The projects which advancements in his laboratory include malignant lymphoma, leukemia, myeloma, as well as other oncological and immunological problems. His recent research expanded to digital pathology and ML approach in the diagnostic hematopathology. Through cutting-edge technologies and broadly colhe is also committed to building a strong, unique, and competitive research program that will ultimately benefit patients.Dr Chen published over 150 papers in peer-reviewed journals, 11 book chapters, 120 abstracts, and delivered many speeches and education courses in major scientific meetings in ASH, USCAP, CSP, ASCP, ISH etc.